ストックスクリーナーアプリを入手
8.20
2.76%
0.22
アフターアワーズ：
8.20
Verastem Inc (VSTM) 最新ニュース
(VSTM) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Verastem Oncology to Participate in Upcoming September Investor Conferences - Business Wire
Verastem Inc. (VSTM) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Verastem: A Rare-Disease Launch Is Financing A KRAS G12D Platform (NASDAQ:VSTM) - Seeking Alpha
Verastem Inc. (VSTM) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Verastem (VSTM) Stock Sees Fair Value Moves Lower As Analysts Cut Revenue Views - Yahoo Finance
Verastem (VSTM) Watch: Records a 1.03% Increase to $6.89 on the Day; Technical View - vinanet.vn
Verastem (NASDAQ:VSTM) Shares Down 8.6%Should You Sell? - MarketBeat
Verastem (VSTM) Q2 2026 Earnings Call Transcript - AOL.com
VSTM | Verastem, Inc. FinancialsRevenue Breakdown - Quiver Quantitative
Verastem (NASDAQ:VSTM) Shares Up 6.4%What's Next? - MarketBeat
Precision Trading with Verastem Inc. (VSTM) Risk Zones - news.stocktradersdaily.com
Verastem (VSTM) Slips 1.35% to $6.58 as Biotech Stock Holds Above Key SupportDebt Free Companies - vinanet.vn
Verastem (NASDAQ:VSTM) Stock Rating Lowered by Wall Street Zen - MarketBeat
Verastem (VSTM) Pulls Back 1.42% to $6.58 as Support HoldsOBV Breakout - vinanet.vn
Verastem, Inc. (VSTM) sees 7.76% ownership reported by Armistice Capital - Stock Titan
Hennion & Walsh Asset Management Inc. Acquires 347,872 Shares of Verastem, Inc. $VSTM - MarketBeat
Verastem Inc (VSTM) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
VSTM Maintains by Mizuho -- Price Target Lowered to $13.00 - GuruFocus
Mizuho lowers Verastem stock price target on valuation to $13 By Investing.com - Investing.com Nigeria
Mizuho lowers Verastem stock price target on valuation to $13 - Investing.com India
Mizuho Adjusts Price Target on Verastem to $13 From $14, Keeps Outperform Rating - Yahoo Finance
Q2 2026 Verastem Inc Earnings Call Transcript - GuruFocus
Q1 2026 Verastem Inc Earnings Call Transcript - GuruFocus
Verastem Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $13 - Moomoo
Weekly Recap: Q2 2026 revenue, cash, losses and RAMP Phase 3 readout - TradingView
Verastem Inc (VSTM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
A Quick Look at Today's Ratings for Verastem(VSTM.US), With a Forecast Between $12 to $18 - Moomoo
Verastem (VSTM) Stock Rallies On Revenue Surge And Pipeline Pressure - Sahm
Verastem Inc (VSTM) Stock News Today - TradingKey
Verastem (NASDAQ:VSTM) Posts Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Verastem Q2 Earnings Call Highlights - MarketBeat
VSTM Maintained by Guggenheim -- Price Target Lowered to $12.00 - GuruFocus
Verastem Oncology (VSTM) Posts Solid Q2 2026; Market Pricing Ref - GuruFocus
State Street Corporation (VSTM) discloses 5.8% beneficial ownership in INC common stock - Stock Titan
Verastem (NASDAQ:VSTM) Shares Gap Up Following Better-Than-Expected Earnings - MarketBeat
Verastem, Inc. Stock 12‑Month Price Target Cut to $14.88, Implies 152% Upside - TradingView
VerastemEnters Amendment No. 3 To Note Purchase Agreement On August 6, 2026SEC Filing - TradingView
Verastem Amends Oberland Financing, Adding Up to $75 Million Revenue-Share Notes Maturing 2033 - TradingView
Verastem Inc (VSTM) (Q2 2026) Earnings Call Highlights: Strong R - GuruFocus
Verastem, Inc. (VSTM) Stock Analysis: 151.69% Potential Upside In Biotech Space - DirectorsTalk Interviews
Verastem Expects Initial Registrational Data for KRAS G12D Inhibitor Cancers This Year - genomeweb.com
How Did Verastem Inc (VSTM) Perform in Q2 2026? Revenue of $40.1 - GuruFocus
Earnings call transcript: Verastem beats Q2 2026 estimates, shares jump after hours - Investing.com
Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Verastem Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Verastem, Inc. 2026: Revenue $40.08M, EPS ($0.35) — 10-Q Summary - TradingView
VERASTEM ($VSTM) Releases Q2 2026 Earnings - Moomoo
Verastem: Q2 Earnings Snapshot - Barchart.com
Verastem (Nasdaq: VSTM) lifts Q2 2026 revenue to $40M, discloses going‑concern risk - Stock Titan
Verastem Q2 revenue jumps on new product sales and milestone - TradingView
Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates - Yahoo Finance
Verastem Inc (VSTM) President and CEO Dan Paterson Sells 1,302 S - GuruFocus
BlackRock, Inc. Trims Verastem Inc (VSTM) Stake in Recent 13DG F - GuruFocus
Verastem, Inc. (VSTM) CEO sells 1,302 shares to cover RSU taxes - Stock Titan
VSTM|Verastem Inc|Price:5.695|Chg%:-0.105 - TradingKey
VSTM Q1 2026 Earnings: Modest EPS Beat Fails to Offset Investor CautionProduct Revenue Analysis - vinanet.vn
A Quick Look at Today's Ratings for Verastem(VSTM.US), With a Forecast Between $14 to $18 - Moomoo
Earnings Preview: Verastem to Report Financial Results Post-market on August 06 - Moomoo
Vanguard Capital Management (VSTM) discloses 4.42M Verastem shares in 13G filing - Stock Titan
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):